Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Preparing to strike

How Ascletis will use its $100M B round to expand beyond HCV

January 6, 2017 10:01 PM UTC

With $100 million in hand Ascletis BioScience Co. Ltd. is poised to repeat what it has done in HCV by hunting for new liver therapies for the China market.

On Jan. 3, Ascletis closed an untranched $100 million series B round led by existing investor C-Bridge Capital. New investors QianHai Equity Investment, Focus Media Jiangnanchun Foundation and WTT Investment also participated, along with existing investors Goldman Sachs and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article